Zoetis (ZTS) Return on Capital Employed (2013 - 2026)
Zoetis' (ZTS) quarterly Return on Capital Employed came in at 27.36% in Q1 2026, down 507.0% year-on-year from 6.72% in Q1 2025, and down 1.18% on a QoQ basis from 27.69% in Q4 2025.
Zoetis (ZTS) Return on Capital Employed (2013 - 2026) Analysis & Trends
Zoetis (ZTS) has 14 years of Return on Capital Employed data on file, last reported at 27.36% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 507.0% year-over-year to 27.36% in Q1 2026; TTM through Mar 2026 was 27.36%, a 507.0% decrease from a year earlier, with the FY2025 full-year figure at 29.01%, down 312.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 27.36%, down from 27.69% in the prior quarter.
- Over the last five years, Return on Capital Employed for ZTS reached as high as 32.8% in Q2 2025 and fell as low as 24.05% in Q1 2023.
- Historically, Return on Capital Employed has averaged 27.71% across 5 years, with a median of 27.36% in 2026.
- Across the five-year window, Return on Capital Employed surged 972 bps in 2022 and sank 507 bps in 2026, its largest moves.
- Year by year, Return on Capital Employed stood at 27.59% in 2022, then fell by 7 bps to 25.72% in 2023, then increased by 25 bps to 32.03% in 2024, then declined by 14 bps to 27.69% in 2025, then decreased by 1 bps to 27.36% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 27.36% in Q1 2026, 27.69% in Q4 2025, and 27.64% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 8.52% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 27.36% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -1.50% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 21.43% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 0.46% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 20.04% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 5.24% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 0.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.36% |
| Dec 31, 2025 | 27.69% |
| Sep 30, 2025 | 27.64% |
| Jun 30, 2025 | 32.80% |
| Mar 31, 2025 | 32.42% |
| Dec 31, 2024 | 32.03% |
| Sep 30, 2024 | 27.24% |
| Jun 30, 2024 | 26.41% |
| Mar 31, 2024 | 26.23% |
| Dec 31, 2023 | 25.72% |
| Sep 30, 2023 | 25.61% |
| Jun 30, 2023 | 25.78% |
| Mar 31, 2023 | 24.05% |
| Dec 31, 2022 | 27.59% |
| Sep 30, 2022 | 27.45% |
| Jun 30, 2022 | 27.69% |
| Mar 31, 2022 | 27.32% |
| Dec 31, 2021 | 22.02% |
| Sep 30, 2021 | 20.63% |
| Jun 30, 2021 | 20.67% |